HANSOH PHARMA (03692): Almonertinib Marketing Authorization Receives Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
Related Articles
ORANGE TOUR (08627) Signs Business Cooperation Agreement with Hong Kong Niuyouguo
SHUANGDENG (06960) repurchased 55,000 shares on November 13 for approximately HK$252,600.
Jiangsu Hengrui Pharmaceuticals (01276): Certain products included in the 2026 National Medical Insurance Catalog
ORANGE TOUR (08627) Signs Business Cooperation Agreement with Hong Kong Niuyouguo
SHUANGDENG (06960) repurchased 55,000 shares on November 13 for approximately HK$252,600.
Jiangsu Hengrui Pharmaceuticals (01276): Certain products included in the 2026 National Medical Insurance Catalog
